Compare SOPH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | EOLS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 407.0M |
| IPO Year | 2021 | 2018 |
| Metric | SOPH | EOLS |
|---|---|---|
| Price | $5.38 | $6.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.50 | ★ $15.50 |
| AVG Volume (30 Days) | 333.8K | ★ 757.7K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $23.09 | $13.27 |
| Revenue Next Year | $19.57 | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $2.83 | $3.86 |
| 52 Week High | $6.30 | $10.20 |
| Indicator | SOPH | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 56.52 |
| Support Level | $4.59 | $6.44 |
| Resistance Level | $5.65 | $6.95 |
| Average True Range (ATR) | 0.40 | 0.31 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 36.24 | 53.33 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.